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Introduction {#sec1}
============

Mitochondria are key organelles with pivotal roles in the bioenergetic and biosynthetic processes of cells. The main function of mitochondria, which are often regarded as the powerhouse of cells, is ATP production through oxidative phosphorylation (OXPHOS). Mitochondrial OXPHOS plays a central role in energy production, which is vital to maintain cellular function and physiology ([@bib64]). There is accumulating evidence for impaired OXPHOS activity in many solid tumor cells ([@bib11]). Furthermore, OXPHOS defects have been described as one of the most common and prominent phenotypes of most cancers ([@bib11], [@bib57]) and are often implicated in several cancer hallmarks ([@bib23]), such as genomic instability ([@bib41]), tumor-promoting inflammation ([@bib50], [@bib14]), and metastasis ([@bib34], [@bib43]). Mitochondria possess their own mitochondrial DNA (mtDNA) genome and the corresponding replication, transcription, and translation machinery required for its maintenance and expression. Human mtDNA encodes 13 hydrophobic core subunits of the OXPHOS system, as well as 2 rRNAs and 22 tRNAs. These 13 proteins are synthesized in the specialized translation machinery called *mitochondrial ribosome*, also known as the mitoribosome ([@bib16]). Mitoribosome is a macrostructure of dual genetic origin, formed by two mitoribosomal RNA components encoded by mtDNA and 82 mitoribosomal proteins (MRPs) encoded by nuclear DNA. Therefore, the balanced expression of rRNAs and MRPs and their well-coordinated assembly are essential for regulation of OXPHOS activity and the resultant energy production.

Recent advances in genomics and proteomics have provided information on the contribution of mitoribosome composition and function in the initiation and promotion of tumors. Many studies have shown that altered expression of several MRPs is closely associated with cancer development and progression as well as the metastasis of many cancer types ([@bib39], [@bib46], [@bib49], [@bib58]). For example, *MRPL11* was decreased in the primary tumor tissues of head and neck squamous cell carcinoma (HNSCC) and was considered a potential biomarker for HNSCC ([@bib30]). In addition, the alternative role of several MRPs, such as *DAP3* ([@bib37]), *MRPS30/PDCD9* ([@bib9]), and *MRPL41* ([@bib13]), as apoptosis-inducing factors has been reported. However, the mechanisms underlying the contribution of MRP alterations to cancer progression remain poorly understood. Moreover, these studies have a limitation on substantiating how MRP alterations affect mitochondrial functions systematically.

As a central organ in a variety of critical biological functions such as homeostasis of carbohydrate, lipid, amino acid, and protein synthesis, the liver is heavily enriched with mitochondria in terms of number and density ([@bib17]), compared with other organs. In addition, most liver diseases including alcoholic liver disease, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, viral hepatitis, and HCC are characterized by mitochondrial dysfunction and are associated with accumulation of damaged mitochondria ([@bib4]). Therefore, MRP alteration might play critical roles in the pathophysiology of liver diseases such as HCC. We have previously reported that reduced expression of MRPL13 is a cause of OXPHOS defects in HCC and promotes the invasiveness of OXPHOS-defective HCC cells, suggesting the potential involvement of mitoribosomal defects in liver cancer progression ([@bib36]). However, it is unclear whether MRPL13 depletion is the only cause for cancerous OXPHOS defects and the associated aggressive phenotype of HCC.

In this study, we demonstrated that patients with HCC with mitoribosome defects had poor prognostic outcomes. In addition, we observed that HCCs with mitoribosome defects exhibited suppressive immune responses, which may allow tumor cells to evade immune surveillance and develop.

Result {#sec2}
======

Mitoribosomal Defect Gene Signature Is a Good Indicator of HCC Prognosis {#sec2.1}
------------------------------------------------------------------------

To elucidate whether mitoribosomal defects are the only primary cause for the OXPHOS defects seen in HCC, we compared mitochondrial biogenesis by investigating mitochondrial translation, transcription, and replication between paired tumors (T) and surrounding tissues (ST) obtained from 15 patients with HCC ([Table S1](#mmc1){ref-type="supplementary-material"}). Among 15 tumor tissues, 8 tissues (53%) showed lower protein levels of COX2, which is an important mtDNA-encoded core subunit of the OXPHOS complex IV, compared with their paired surrounding tissues ([Figures S1](#mmc1){ref-type="supplementary-material"}A--S1E). Unexpectedly, among those 8 tissues, only one case showed decreased protein levels of mitochondrial transcription factor A (TFAM), a key mitochondrial transcription factor. However, the other cases harbored even higher TFAM levels ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1C). Moreover, when we further examined the mtDNA copy number, only one case of eight tumor tissues showed a slight decrease in mtDNA levels ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1D). These results imply that mitochondrial replication and its transcription activity are not the main contributors to the low expression of an mtDNA-encoded protein ([Figure S1](#mmc1){ref-type="supplementary-material"}E).

As the mitoribosome, comprising 82 MRPs ([@bib45]), is a huge and complex structure, it is plausible that co-expression of MRPs may play a critical role in the mitoribosome assembly and translation into functional proteins. With this concern, we examined the expression of MRPs in HCC by analyzing The Cancer Genome Atlas (TCGA) transcriptome data (n = 371, [Figure 1](#fig1){ref-type="fig"}A). Interestingly, we observed that the distribution of overall expression levels of MRPs was not different between non-tumor (NT) and primary tumor (PT) tissues ([Figure 1](#fig1){ref-type="fig"}B). However, the NT group showed a well-coordinated expression of MRPs in each sample, whereas the PT group showed more diverse expression levels of MRPs in each sample ([Figures 1](#fig1){ref-type="fig"}C and 1D). Moreover, the NT group, compared with the PT group, showed a closer correlation among the expression levels of MRPs ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). These results imply that the NT group had intact mitoribosomal integrity, showing a well-coordinated expression of MRPs, whereas the PT group lost its mitoribosomal integrity and showed dysregulated expression of MRPs. Thus, we suggest that the dysregulated MRP expression in HCC may play important roles in HCC development or progression.Figure 1Mitoribosomal Defect Gene Signature Is a Good Indicator of HCC Prognosis(A) Schematic view of the analysis of MRPs to define three distinctive signatures (Up-MRPs, Dn-MRPs, and Other-MRPs).(B) Comparison of MRPs\' expression between NT and PT.(C) Heatmap shows the expression of 82 MRPs in 371 PT and 50 NT samples from TCGA-LIHC cohort.(D) Comparison of maximum absolute deviation (MAD) among MRPs\' expression between NT and PT.(E) (Top) Enrichment of three distinctive signatures (Up-MRPs, Dn-MRPs, and Other-MRPs) among PT. (Bottom) Heatmap shows the expression of variable MRPs (n = 38) among PT. (Right) Bar plot indicates the fold difference in the expression of variable MRPs (n = 38) between PT and NT.(F and G) Mitoribosome defect scores (MDSs) were calculated based on the three distinctive signatures (Up-MRPs, Dn-MRPs, and Other-MRPs) and total MRPs; MDS~*up*~, MDS~*dn*~, MDS~*other*~, and MDS~*all*~, respectively. Heatmap indicates the association of MDS~*up*~ and MDS~*dn*~ with Cancer Hallmark gene sets. According to the direction of the association between MDS~*up*~ and MDS~*dn*~, gene sets were classified into the opposite, Only-MDS~*up*~, Only-MDS~*dn*~, or common, which were associated with MDS~*up*~ and MDS~*dn*~ in the opposite manner, MDS~*up*~ specifically, MDS~*dn*~ specifically, or in the same direction, respectively. A positive or negative association is shown in red or blue, respectively. Gene set with a non-significant association (p \> 0.001) is shown in the blank (F). Forest plot indicates hazard ratios for MDSs based on the Cox-regressional univariate survival analysis (G).(H) Comparison of MDS between male (n = 250) and female (n = 121) samples from TCGA-LIHC cohort. Boxplots of MDSs of males and females are shown as first quartile, median, and third quartile (bottom box, middle line, and top box, respectively). Whiskers represent the minimum and maximum values.See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}; [Table S2](#mmc1){ref-type="supplementary-material"} and [Table S3](#mmc1){ref-type="supplementary-material"}

To evaluate whether the expression of MRPs contributes to the development and progression of HCC, we generated three unique MRP signatures, 12 up-MRPs, 6 down-MRPs, and 20 other-MRPs, by comparing the MRP expression between PT and NT (permuted Student\'s t test p \< 0.05 and fold difference \>0.3, [Transparent Methods](#mmc1){ref-type="supplementary-material"}; [Figures 1](#fig1){ref-type="fig"}A and 1E; [Table S2](#mmc1){ref-type="supplementary-material"}). Thereafter, by performing gene set enrichment analysis (GSEA), the expression enrichment of these signatures was measured in each of the tumor samples ([Figure 1](#fig1){ref-type="fig"}E). Interestingly, most HCC samples demonstrated higher expression of up-MRPs and lower expression of the down-MRPs. This may indicate that the expression of each of the up-MRPs and down-MRPs is well coordinated in tumor cells.

To estimate the degree of mitoribosome defects in individual samples, we then designated the enrichment scores (NES, normalized enrichment score) of the three MRP signatures (up-MRPs, down-MRPs, or other-MRPs) and transformed the NES as mitoribosome defects scores (MDS), MDS~*up*~, MDS~*dn*~, and MDS~*other*,~ to reflect the direction of the up and down signatures (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}). When evaluating whether these MDSs were associated with cancer-related features using 50 cancer hallmark gene sets ([@bib38]) (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}), we observed that most of the cancer gene sets showed closely correlated expressions with MDS~*dn*~ and negatively correlated expression with MDS~*up*~ ([Figure 1](#fig1){ref-type="fig"}F; [Table S3](#mmc1){ref-type="supplementary-material"}). In addition, MDS~*dn*~ showed significant correlations with the expression of gene sets for the unfolded protein response (r = 0.417, p = 5.083 × 10^−17^) and glycolysis (r = 0.308, p = 1.303 ×10^−9^) and negative correlations with lipid metabolism-related gene sets (i.e., fatty acid metabolism and adipogenesis) ([Figure 1](#fig1){ref-type="fig"}F; [Table S3](#mmc1){ref-type="supplementary-material"}). Remarkably, MDS~*dn*~ showed the strongest negative correlation with OXPHOS (r = −0.565, p = 1.020 ×10^−32^). This may imply that mitoribosomal defects induced by the suppression of down-MRPs are closely associated with OXPHOS dysfunction. Moreover, survival analysis based on the Cox regressional hazard model showed that only MDS~*dn*~ was significantly associated with poor prognosis (p = 8.479 × 10^−3^) ([Figure 1](#fig1){ref-type="fig"}G). These results suggest that mitoribosomal defects invoked by the decreased expression of down-MRPs may play a critical role in HCC prognosis. In addition, these findings indicate that MDS~*dn*~ is a good indicator of mitochondrial dysfunction and HCC prognosis, emphasizing that our MDS scoring system is an important new tool that successfully reflects the mitochondrial dysfunction-related cancer features in HCC. Furthermore, there was no significant difference found in the comparison of MDS between males (n = 250) and females (n = 121), implying that mitoribosomal defects may not be affected by sex differences ([Figure 1](#fig1){ref-type="fig"}H).

Identification of Molecular Features Linked to Mitoribosomal Defects {#sec2.2}
--------------------------------------------------------------------

To advance the clarification of the underlying molecular features related to mitoribosomal defects in HCC, we stratified TCGA HCC samples into high- and low-mitoribosome defect (MD) subtypes, i.e., H-MD (\>upper quartile MDS~*dn*~) and L-MD (\<lower quartile MDS~*dn*~), respectively. GSEA analysis (MsigDB. V. 6.1) revealed that H-MD was depleted in the mitochondrial function-related gene sets, such as OXPHOS, fatty acid metabolism, and reactive oxygen species (ROS) pathway, as well as the mitochondrial structure-related gene sets, such as mitochondrial matrix, envelope, membrane, and protein complex ([Table S4](#mmc1){ref-type="supplementary-material"}; [Figures 2](#fig2){ref-type="fig"}A, 2B, and [S3](#mmc1){ref-type="supplementary-material"}A--S3C). In contrast, the H-MD group revealed enriched expression of cell cycle-related gene sets (i.e., mitotic spindle, PI3K/AKT/mTOR axis signaling). Other cancer-related gene sets were also enriched in the H-MD, including transforming growth factor (TGF)-β signaling ([@bib6]), WNT/β-catenin signaling ([@bib29]), nuclear factor-κΒ signaling ([@bib40]), epithelial to mesenchymal transition (EMT), inflammatory response, and interleukin (IL)-6/JAK/STAT3 axis signaling ([Table S4](#mmc1){ref-type="supplementary-material"}; [Figures 2](#fig2){ref-type="fig"}C and [S4](#mmc1){ref-type="supplementary-material"}A--S4C). These results indicate that mitochondrial dysfunction, as a result of mitoribosomal defects, may be critically involved in cell transformation and progression of aggressive HCC. Furthermore, in the Kaplan-Meier survival analysis, the H-MD group showed worse prognostic outcomes of overall survival compared with L-MD ([Figure 2](#fig2){ref-type="fig"}D). By comparing the gene expression between H-MD and L-MD, we identified 83 upregulated and 161 downregulated differentially expressed genes (DEGs) in H-MD (permutated Student\'s t test false discovery rate \[FDR\] \<0.005 and fold change \>1, [Figures 2](#fig2){ref-type="fig"}E--2G; [Table S5](#mmc1){ref-type="supplementary-material"}). Among the upregulated DEGs, immune response-related genes, such as secreted phosphoprotein 1 (*SPP1*), integrin subunit beta 1 (*ITGB1*), and immunoglobulin heavy constant gamma 1 (*IGHG1*), as well as cell adhesion-related genes such as *CD24*, stratifin (*SFN*), and epithelial cell adhesion molecule (*EPCAM*), were the most highly expressed in H-MD ([Figure 2](#fig2){ref-type="fig"}E, *pink-colored box*). On the contrary, genes related to metabolism, such as carbamoyl-phosphate synthase 1 (*CPS1*), serum amyloid A1 (*SAA1*), cytochrome P450 family 8 subfamily B member 1 (*CYP8B1*)*,* and tyrosine aminotransferase (*TAT*), showed the lowest expression in the H-MD group ([Figure 2](#fig2){ref-type="fig"}E, *blue-colored box*). Interestingly, according to the Human Protein Atlas ([@bib55]) (<https://www.proteinatlas.org/>), more than half of the downregulated DEGs (82/161) are liver tissue-specific genes, including *CPS1*, *SAA1*, *TAT*, and *HPD*, indicating that mitoribosomal integrity is also essential in maintaining the liver\'s intrinsic functions ([Table S5](#mmc1){ref-type="supplementary-material"}). Similarly, Gene Ontology (GO) analysis of DEGs demonstrated that genes involved in fundamental mitochondrial functions such as catabolic, biosynthetic process and oxidation-reduction processes were significantly downregulated, whereas those linked to immune cell infiltration, inflammatory response, and extracellular matrix (ECM) organization were highly upregulated in H-MD ([Figure 2](#fig2){ref-type="fig"}H). These results indicate the potential impact of mitoribosome defects on the tumor microenvironment concerning the immune response.Figure 2Identification of Molecular Features Linked to Mitochondrial DefectsBased on the MDS~*dn*~, TCGA-LIHC samples were stratified into the subgroup with higher mitoribosome defect (H-MD) and one with lower mitoribosome defect (L-MD), and molecular features associated with H-MD or L-MD were compared.(A--C) GSEA results based on the OXPHOS (A), mitochondria respiratory chain complex assembly (B), and TGF-β signaling (C) were shown. Normalized enrichment scores (NES) and FDR for each gene set are noted.(D) Overall survival time of H-MD and L-MD was compared based on the Kaplan-Meier survival analysis.(E) Volcano plot indicates fold change (FC) and FDR based on the permutation t test between H-MD and L-MD groups. Differentially expressed genes (DEGs) were marked with red- or blue-colored points (FC \> 1 or \< −1 & FDR \<0.005, respectively).(F) The expression of upregulated (n = 83) or downregulated (n = 161) DEGs in either H-MD or L-MD is shown. Samples are represented in columns, grouped by H-MD or L-MD.(G) Enrichment plots based on the 83 upregulated genes and 161 downregulated genes are shown in the left and right panels, respectively. NES and FDR for each gene set are noted.(H) Gene ontology (GO) analysis was performed based on the up and down DEGs. The -log~10~(p value) is shown in red and blue bars for up- and downregulated genes, respectively.See also [Figure S3](#mmc1){ref-type="supplementary-material"}; [Table S4](#mmc1){ref-type="supplementary-material"} and [S5](#mmc1){ref-type="supplementary-material"}.

Mitoribosomal Defects Are Closely Associated with Immune Cell Response in HCC {#sec2.3}
-----------------------------------------------------------------------------

Based on GO analysis, we interrogated the relevance of mitoribosomal defects to immune response signaling in detail. First, we employed the recently reported immune signatures (n = 112) derived from an immune-specific subclass of HCC ([@bib48]). The H-MD group showed higher enrichment for the overall HCC immune signature ([@bib48]) than did the L-MD group ([Figure 3](#fig3){ref-type="fig"}A). Furthermore, among the immune system genes with significantly higher expression in H-MD (n = 21, permutated Student\'s t test FDR \<0.01 and fold change \>0.5; [Figure S4](#mmc1){ref-type="supplementary-material"}A), *COL1A1*, *COL1A2*, and *POSTN* were prominently expressed in the H-MD group ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Considering their function in ECM, we investigated whether or not mitoribosomal defects were associated with cancer-associated ECM (C-ECM). It was observed that the H-MD group was enriched with the C-ECM signature ([@bib10]) ([Figure 3](#fig3){ref-type="fig"}B). Furthermore, the H-MD group was enriched with the activated stroma-related genes ([@bib42]), but not with normal stroma-related genes ([@bib42]) ([Figures 3](#fig3){ref-type="fig"}C and 3D). These results are indicative of the possibility that mitoribosome defects may selectively affect the neighboring cells to perturb the HCC microenvironment. To delineate the repertoire of neighboring cells in the microenvironment, we used the inferred proportion for 64 immune and stromal cell types based on *xCell* analysis ([@bib3]) and compared the proportion of infiltrated immune cells between H-MD and L-MD (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}, and [Figures 3](#fig3){ref-type="fig"}E and 3F; [Table S5](#mmc1){ref-type="supplementary-material"}). Interestingly, suppressive immune cells favorable for cancer cells including mast cells, Th2 cells, and regulatory T cells showed more infiltration ([Figure 3](#fig3){ref-type="fig"}E), whereas stimulatory immune cells related to anti-cancer immunity such as CD8+ naive T cells, NK T cells (NKT), and Th1 cells were less infiltrated in the H-MD than in the L-MD subtype ([Figure 3](#fig3){ref-type="fig"}F). These results suggest that mitoribosome defects may contribute to the creation of a more favorable microenvironment by suppressing immune responses and promoting evasion from immune surveillance. Next, we examined the link of mitoribosomal defects with immune-modulatory cytokines using 25 immune inhibitors, 28 immune stimulators, 6 major histocompatibility complex (MHC) class I, 10 MHC class II, and 3 MHC non-classified molecules ([Transparent Methods](#mmc1){ref-type="supplementary-material"}, [Table S7](#mmc1){ref-type="supplementary-material"}). This analysis revealed that most cytokines, except for *IL6R* and *ICOSLG* (*green-colored box*), were more highly expressed in the H-MD than in the L-MD subtype and were positively associated with mitoribosomal defects ([Figure 3](#fig3){ref-type="fig"}G), implying a more active immune contexture of the H-MD group.Figure 3Mitoribosomal Defects Are Closely Associated with Immune Cell Response in HCC(A--D) preRanked GSEA was performed based on the HCC immune-related signature (A), cancer-associated ECM signature (B), activated stroma-associated signature (C), and normal stroma-associated signature (D). NES for each gene set is compared between H-MD and L-MD.(E and F) The proportion of immune cells with pro-cancer (Mast cells, Th2 cells, and T~reg~s) (E) and with anti-cancer properties (CD8+ T cells, NK-T cells, and Th1 cells) (F) are compared between H-MD and L-MD based on the *xCell* analysis output.(G) The average expression values of immune-modulatory cytokines in either H-MD or L-MD group are shown in colored scale. According to their immune response-related properties, cytokines were classified as inhibitory; stimulatory; MHC classes I, II, and non-classified (NC) and marked with green-, purple-, sky blue-, navy blue-, and gray-colored bars, respectively. A significant association with MDS~*dn*~ is shown as a colored scale, and non-significant association is shown as blank.(H) Permutation t test was performed between H-MD and L-MD among the immune-modulatory cytokines. The x axis indicates the expression fold change between H-MD and L-MD, and the y axis indicates the -log~10~FDR for each cytokine. Cytokines significantly associated with MDS~*dn*~ are depicted in color coded in (G) according to their immune-related properties.(I) *TGFB1* expression is compared between H-MD and L-MD. Boxplots are shown as first quartile, median, and third quartile (bottom box, middle line, and top box, respectively) with Welch two-sample t test p values. Whiskers represent the minimum and maximum values.See also [Figure S4](#mmc1){ref-type="supplementary-material"} and [S5](#mmc1){ref-type="supplementary-material"}; [Tables S6](#mmc1){ref-type="supplementary-material"} and [S7](#mmc1){ref-type="supplementary-material"}.

Among the immune molecules, *TGFB1* was the most highly expressed gene in H-MD with a significant association with mitoribosomal defects ([Figures 3](#fig3){ref-type="fig"}G--3I). This result is further supported by our previous report that *TGFB1* is one of the common mitochondrial defect signature genes identified from various mitochondrial defect models ([@bib35]). Furthermore, as shown in the GSEA result in [Figure 2](#fig2){ref-type="fig"}C, TGF-β signaling was significantly enriched in H-MD. These findings raise the possibility that *TGFB1* may play a key role in mediating the effect of mitoribosomal defects within the tumor microenvironment. TGF-β signaling is known to exhibit either tumor-suppressive or oncogenic properties, depending on the tumor stage. Moreover, HCC tissues enriched with a late-responsive TGF-β signature showed a significantly poorer prognosis with shorter mean survival time, displaying an invasive phenotype and increased tumor recurrence compared with the tissues enriched with an early responsive TGF-β signature ([@bib15]). Consequently, we examined the relevance of mitoribosomal defects with the early- and late-responsive TGF-β signatures. In this analysis, we found that the late TGF-β signature was more enriched in H-MD, whereas few differences in the enrichment of the early TGF-β signature were observed between subtypes ([Figures S4](#mmc1){ref-type="supplementary-material"}B and S4C), indicating a close association of mitoribosomal defects with the tumor-promoting TGF-β signature. To elucidate the effect of mitoribosomal defects on the tumor microenvironment, we assessed the TGF-β responses in endothelial cells, fibroblasts, T cells, and macrophages based on the cell type-specific TGF-β response signatures (TBRS) derived from cells cultured with TGF-β ([@bib7]) (i.e., E-TBRS, F-TBRS, T-TBRS, or M-TBRS). In this analysis, all the TBRS were highly enriched in the H-MD group and were strongly associated with mitoribosomal defects ([Figures S4](#mmc1){ref-type="supplementary-material"}D and S4H). Furthermore, we found a robust direct correlation among them, implying their concurrent expression among samples with mitoribosomal defects to a large extent ([Figure S4](#mmc1){ref-type="supplementary-material"}H). These results suggest that mitoribosomal defect-mediated TGF-β expression may be an essential regulator of various cell types in the tumor microenvironment, thereby promoting HCC progression.

Mitoribosomal Defects Regulate Immune Modulator Expression in HCC Cells {#sec2.4}
-----------------------------------------------------------------------

Next, to validate the involvement of mitoribosomal defects in HCC immune modulator expression, we analyzed the transcriptome data of HCC cell lines from the Cancer Cell Line Encyclopedia (CCLE) ([Transparent Methods](#mmc1){ref-type="supplementary-material"}). By applying the same approach in HCC tissue samples, we inferred MDS~*dn*~ in cancer cell lines and categorized cancer cell lines into the H-MD type or L-MD type, respectively ([Figure 4](#fig4){ref-type="fig"}A and [Table S8](#mmc1){ref-type="supplementary-material"}). First, to validate the strong association of mitoribosomal defects with immune modulators ([Figure 3](#fig3){ref-type="fig"}G), we compared their expression between H-MD and L-MD. This analysis confirmed the upregulation of *TGFB1* and colony-stimulating factor-1 (*CSF1*) and the downregulation of *ICOSLG* in H-MD-type cells ([Figures 4](#fig4){ref-type="fig"}B, 4C, and [S5](#mmc1){ref-type="supplementary-material"}A). These findings suggest that they are key immune modulators mediating the immune response induced by mitoribosomal defects in HCC cells. As *CSF1* is involved in the immunosuppressive nature of the HCC microenvironment via the S*PP1*/*CSF1*/*CSF1R* axis ([@bib63]), we assessed the association of mitoribosomal defects with the CSF1 signaling axis. In addition to the upregulated expression of secreted phosphoprotein 1 (*SPP1*), the CSF1 axis was positively associated with mitoribosomal defects showing higher enrichment in H-MD-type cells ([Figures 4](#fig4){ref-type="fig"}D, 4E, and [S5](#mmc1){ref-type="supplementary-material"}B). As a proof of concept, we selected two H-MD-type (JHH4 and SNU475) and two L-MD-type cell lines (HepG2 and JHH5) and confirmed the low to rare expression of a few representative down-MRPs in the H-MD-type compared with L-MD-type cells ([Figure 4](#fig4){ref-type="fig"}F). Following the unified nomenclature for MRP ([@bib16]), we used mS31 and mL46 for proteins of *MRPS31* and *MRPL46*. We further examined whether down-MRPs were truly linked to the integrity of mitoribosome. When cellular components were subjected to sucrose gradient sedimentation, JHH4 showed a lower level of mitochondrial ribosomal subunit assembly (28S small, 39S large, and 55S total subunits) compared with HepG2 ([Figure 4](#fig4){ref-type="fig"}G). The assembly profile of JHH4 was not clearly distorted, indicating overall assembly was decreased due to the low MRP expression. Moreover, the protein levels of mitochondria-encoded genes, *MT-CO2* and *MT-ND6*, were lower in the H-MD than in the L-MD type, whereas the protein level of the nuclear-encoded gene (succinate dehydrogenase complex flavoprotein subunit A; *SDHA*) was unchanged ([Figure 4](#fig4){ref-type="fig"}F). When HCC cells were exposed to MG132, which has been verified as an inhibitor of mitochondrial protein ([@bib33]), MT-COX2 level of H-MD-type cells was not restored to the basal level of L-MD-type cells, whereas that of the L-MD-type cell was further augmented ([Figure 4](#fig4){ref-type="fig"}H). These results indicate that the two H-MD-type cell lines support a decreased mitochondria-specific translational capacity, which is associated with mitoribosomal defects, rather than weak protein stability. We further validated that the two H-MD-type HCC cells, JHH4 and SNU475, harbored increased *TGFB1* and *CSF1* mRNA levels, compared with the L-MD-type cells ([Figures 4](#fig4){ref-type="fig"}I and 4J). When L-MD-type cell lines, HepG2 and JHH5, were exposed to doxycycline, which is a mitoribosome-specific translation inhibitor, the mtDNA-encoded protein expression of COX2 and ND6 was effectively decreased. However, *TGFB1* and *CSF1* mRNAs were significantly increased ([Figures 4](#fig4){ref-type="fig"}K--4P). These results clearly indicate that mitoribosomal defects in HCC cells themselves induce the expression and release of *TGFB1* and *CSF1*, suggesting their crucial involvement in fostering an immune-suppressive environment.Figure 4Mitoribosomal Defects Regulate HCC Immune Modulator Expression in HCC CellsFor validation in the HCC cell lines, transcriptome data for HCC cell line was obtained from CCLE dataset. MDS~*dn*~ for each HCC cell line was calculated ([Methods](#sec4){ref-type="sec"}).(A) According to the increasing order of MDS~*dn*~, MDS~*dn*~ of each HCC cell line is plotted. HCC cell lines representing H-MD or L-MD subgroup are marked in red or blue color, respectively.(B--E) Messenger RNA expression of *TGFB1* (B), *CSF1* (C), and SPP1 (D) are compared between H-MD-type and L-MD-type HCC cell lines of (A). The preRanked GSEA was performed based on the *SPP1/CSF1/CSF1R/PDL1* signal axis, which is related to a sensitivity of anti-PD-1 immunotherapy in patients with HCC (E). The NES was compared between D- and ND-type cell lines (E). Boxplots are shown as first quartile, median, and third quartile (bottom box, middle line, and top box, respectively) with Welch two-sample t test p values. Whiskers represent the minimum and maximum values.(F) Protein levels of Dn-MRPs (*MRPS31* and *MRPL46*) and mitochondrial-encoded genes (*MT-CO2* and *MT-ND6*) were validated in representative H-MD-type (JHH4 and SNU475) and L-MD-type cell line (HepG2 and JHH5) by western blot. According to new nomenclature for mitoribosomal protein, we used mS31 and mL46 for proteins of *MRPS31*and *MRPL46*.(G) Sucrose gradient sedimentation analysis of MRPs from whole-cell lysates of the indicated cell lines. According to the new nomenclature for mitoribosomal protein, we used mS31, uS22, uS15, uL15, uL13, uL11, and mL46 for proteins of *MRPS31*, *MRPS22*, *MRPS15*, *MRPL13*, *MRPL11*, and *MRPL46*.(H) HCC cells were exposed to various doses of MG132 for 12 h and subjected to western blot analysis. DMSO was used as a vehicle (V).(I and J) Messenger RNA expression of *TGFB1* (I) and *CSF1* (J) in two H-MD-type (JHH4 and SNU475) and two L-MD-type cell lines (HepG2 and JHH5) were monitored by qRT-PCR.(K--P) L-MD-type cell lines (HepG2 and JHH5) were exposed to various doses of mitochondria-specific translation inhibitor, doxycycline (DOX) for 72 h. JHH5 cells showed higher sensitivity to DOX than HepG2. Western blot analysis for the expression level of mtDNA-encoded proteins, COX2 and ND6, and nuclear DNA-encoded SDHA protein was also examined to prove the inhibitor\'s specificity (K and N). Messenger RNA expression of *TGFB1* (L and O) and *CSF1* (M and P) were examined by qRT-PCR. Bar plots are represented as mean ± SEM. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.005 (Student\'s t test, DOX treated group versus non-treated group).See also [Table S8](#mmc1){ref-type="supplementary-material"}.

TBRS Induced by MRP Defects Mediates an Aggressive Phenotype in HCC {#sec2.5}
-------------------------------------------------------------------

Besides suppressing the immune response, TBRS modulates cancer cell activity mainly through EMT in HCC ([@bib12], [@bib47]). Therefore, we evaluated the association of TBRS with mitoribosomal defects in HCC cells. When the TBRS of epithelial cells ([@bib44]) was applied to the transcriptome data of HCC cells, mitoribosomal defects showed a strong association with TBRS, as corroborated by the increased enrichment of TBRS in H-MD-type than L-MD-type cells ([Figures 5](#fig5){ref-type="fig"}A and 5B). We also found that among the common HCC molecular subclass described by [@bib25] ([@bib25]), mitoribosomal defects had a strong positive association with the S1 subtype, yet negative associations with both the S2 and the S3 signatures ([Figure 5](#fig5){ref-type="fig"}C). These findings suggest that mitoribosomal defects are selectively associated with the molecular features of the S1 subtype. As vascular invasion is a well-defined clinical feature for the S1 subtype, we assessed the association of mitoribosomal defects with an invasive signature from a multi-cancer study ([@bib2]). Consistently, mitoribosomal defects were positively associated with cancer cell invasiveness ([Figure 5](#fig5){ref-type="fig"}D). Furthermore, invasive features were highly enriched in H-MD-type cells ([Figure 5](#fig5){ref-type="fig"}E). To examine whether the invasion ability of HCC cells was influenced by mitoribosomal defect-mediated TGF-β signaling, we implemented the invasion assay using H-MD-type cells (JHH4 and SNU475) and L-MD-type (HepG2 and JHH5) HCC cells. H-MD-type cells showed higher invasion activity than L-MD-type cells despite their delayed cell growth rate ([Figures 5](#fig5){ref-type="fig"}F and 5G). When we incubated H-MD-type cells with culture medium containing TGF-β-neutralizing antibodies to block TGF-β signaling, TBRS was effectively abrogated as evidenced by decreased Smad2 phosphorylation ([Figures 5](#fig5){ref-type="fig"}H and 5I). This indicated that H-MD-type cells truly released TGF-β and that their TBRS was active. Moreover, we found that the invasion capacity of H-MD-type cells was significantly reduced by eliminating TBRS ([Figures 5](#fig5){ref-type="fig"}J and 5K). These results indicate that mitoribosomal defect-mediated TGF-β release regulated the invasion activity of H-MD-type cells in an autocrine manner.Figure 5TBRS Induced by MRP Defects Mediates an Aggressive Phenotype in HCC(A and B) The association of mitoribosomal defects in HCC with TBRS was recapitulated in HCC cell lines. For TBRS in HCC cell line, signatures of epithelial cells (Epi_TBRS) were used. The MDS~*dn*~ shows a significant correlation with Epi_TBRS (A). NES based on Epi_TBRS was compared between H-MD- and L-MD-type HCC cell lines (B).(C) MDS~*dn*~ shows differential associations with HCC sub-classification signatures (Hoshida_S1, S2, and S3).(D and E) The association of mitoribosomal defect with cancer cell invasiveness was examined. preRanked GSEA was performed based on the invasion signature defined by Anastassiou et al. MDS~*dn*~ shows a significant association with cancer cell invasiveness (D). NES based on cancer cell invasiveness signature (Anastassiou et al.) was compared between H-MD and L-MD-type HCC cell lines (E).(F) Cell invasion activity was assayed using Matrigel-coated Transwell as described in the [Transparent Methods](#mmc1){ref-type="supplementary-material"} section. Representative images are shown in the right panel.(G) Cell growth rates were monitored by counting the trypan blue-negative viable cells using the Countess automated cell counter.(H--K) TGF-β signaling in H-MD-type HCC cell lines (SNU475 and JHH4) was abolished by exposure to various concentrations of neutralizing antibodies for TGF-β (GTX14052, GeneTex Inc., Irvine, CA) for 24 h. Normal mouse IgG (sc-2025, Santa Cruz Biotechnology, Inc., Dallas, TX) was used as control. Phosphorylated SMAD2 (P-smad2) and total SMAD2 (T-smad2) levels were examined by western blot to validate the extent of TGF-β signaling inhibition (H and I). Then, the cell invasion assay was performed (J and K). Representative images for invaded cells are shown in the right panels. Boxplots are shown as first quartile, median, and third quartile (bottom box, middle line, and top box, respectively) with Welch two-sample t test p values. Whiskers represent the minimum and maximum values. Bar plots are represented as mean ± SEM. ^∗^p\<0.05, ^∗∗^p\<0.01, ^∗∗∗^p\<0.005 (Student's t-test, DOX treated group vs. non-treated group).See also [Figure S6](#mmc1){ref-type="supplementary-material"}; [Table S9](#mmc1){ref-type="supplementary-material"}.

Last, we postulated that the mitoribosomal defect-mediated invasion capacity of H-MD-type cells was also closely linked with HCC recurrence. To test this hypothesis, we performed GSEA using HCC recurrence signatures ([@bib59], [@bib26], [@bib27], [@bib61], [@bib32]) and examined their association with mitoribosomal defects ([Table S8](#mmc1){ref-type="supplementary-material"}). Based on the upregulated or downregulated genes in the recurred HCC samples from [@bib59] and [@bib26], we investigated the association of mitoribosomal defects with HCC recurrence. In this analysis, the H-MD subtype showed increased enrichment of upregulated genes and decreased enrichment of downregulated genes, indicating that mitoribosomal defects in HCC cells were strongly associated with HCC recurrence ([Table S9](#mmc1){ref-type="supplementary-material"} and [Figures S6](#mmc1){ref-type="supplementary-material"}A--S6D). Although early recurrence was one of the clinical features of the S1 subtype ([@bib25]), there was no significant association of early recurrence signatures with mitoribosomal defects ([Table S9](#mmc1){ref-type="supplementary-material"} and [Figures S6](#mmc1){ref-type="supplementary-material"}E and S6F). Considering that the distinct genetic features were involved in the early and late recurrence of HCC, these results implied that mitoribosomal defects were selectively associated with molecular features of late recurring HCC.

Taken together, these results indicate that the mitoribosomal defects caused by aberrant expression of down-MRPs are one of the causes of OXPHOS impairment and the related overall mitochondrial dysfunction, further introducing a novel mitochondria-related HCC hallmark. Also, our findings demonstrate that mitoribosomal defects actively participate in establishing a favorable microenvironment by recruiting suppressive immune cells and activating the ECM to increase the invasion capacity of tumor cells. In detail, the TGF-β signaling pathway is a crucial mechanism to mediate mitoribosomal defects with the diverse aggressive molecular features of HCC. This implies that a set of down-MRPs may be used as good prognostic markers for HCC and that therapeutics co-targeting TGF-β and down-MRPs can be a more selective strategy for the treatment of HCC with mitoribosomal defects.

Discussion {#sec3}
==========

As a specialized mitochondrial translational machinery, the mitoribosome integrity is essential for OXPHOS function including ATP production in an aerobic manner. Thus, aberrant expression of the MRPs comprising mitoribosomes may result in critical defects in energy production and in the overall regulation of cellular respiration, further resulting in deregulated cellular energetics, which has recently been added as a cancer hallmark ([@bib23]). There are several underlying mechanisms such as mtDNA mutations, mitochondrial enzyme defects, or altered oncogenes/tumor suppressors explaining the close association of mitochondrial dysfunction with deregulated cellular energetics ([@bib56], [@bib5]). However, to date, the contribution of mitoribosomal defects on deregulated cellular energetics has not been studied well. Moreover, metabolic reprogramming in hepatocytes has been proposed as a key component in the progression to malignant HCC cells ([@bib8]). Thus, we hypothesized that mitoribosomal defects induced by MRP aberration may contribute to the initiation and progression of HCC. To the best of our knowledge, this study is the first to systematically profile the MRPs in HCC and elucidate how mitoribosomal defects affect HCC progression. In this study, we identified a signature reflecting mitoribosomal defects, consisting of six downregulated MRPs, MRPL39, MRPL46, MRPL34, MRPL54, MPLS6, and MPLS31, and devised a scoring metric of the mitoribosome defect using these genes and designated it as MDS. Interestingly, we found that MDS had close associations with not only essential mitochondrial functions such as OXPHOS but also aggressive phenotypes such as the cell cycle and EMT. Moreover, MDS also had prognostic significance in indicating shorter overall survival time. These results demonstrated that the MDS could reflect the oncogenic potential of mitoribosomal defect. In addition, the differential associations of MDS with infiltrated immune cells, associations such as higher MDS in the tumor showed increased enrichment with immune cells having suppressive characteristics and less enrichment with immune cells having stimulatory characteristics, indicated that mitoribosomal defects attract a differential repertoire of immune cells and provide a favorable microenvironment for cancer cells by recruiting immune cells with suppressive activity and promoting escape from immune surveillance.

Among suppressive cytokines, *TGFB1* showed a significant association with mitoribosomal defects as *in vitro* analysis using the H-MD-type and L-MD-type HCC cell lines showed increased *TGFB1* expression in the H-MD type and mitoribosome defect-induced TBRS activation affected cancer cell invasion. Based on our findings, we postulate that *TGFB1* plays a crucial role in constructing a favorable microenvironment that is induced by the mitoribosomal defects. As a pleiotropic cytokine, TGF-β regulates cellular proliferation, differentiation, and ECM production. Aberrant expression of TGF-β or dysregulated TBRS has been involved in the pathogenesis of a variety of diseases, including cancer and fibrosis. Moreover, TGF-β was elevated in both the plasma and tumor tissues of patients with HCC ([@bib22]), and TBRS activation was considered to engage in hepatocarcinogenesis and to contribute to EMT in HCC models ([@bib21]). Interestingly, Yi et al. recently reported a direct association between TGF-β with mitochondrial dysfunction in HCC, demonstrating that *TGFB1* expression was augmented in mitochondria-depleted ρ0 HCC cell lines and that TBRS was involved in the EMT induced by mitochondrial dysfunction ([@bib60]). In addition, a recent study using human peripheral and tumor-associated lymphocytes, tumor-derived TGF-β, demonstrated the suppression of a key antitumor function of CD4^+^ T cells and interferon-γ production by inhibiting the mitochondrial respiration ([@bib18]). Considering these findings, we suggest TGF-β as a key effector mediating the effect of mitoribosomal defect on HCC progression and immune evasion.

However, we could not clearly present how mitoribosome defects in HCC upregulate the expression of *TGFB1* and activate TBRS, or clarify how activated TBRS fosters a cancer-favorable microenvironment and suppresses anti-tumor immunity. One plausible explanation for this can be the rise of mitochondrial ROS as a result of OXPHOS dysfunction in mitoribosome-defective HCC. Furthermore, Jain et al. reported that mitochondrial ROS regulated TBRS and augmented TGF-β-mediated transcription in primary normal human lung fibroblasts ([@bib28]). Depending on their concentration and cellular compartmentalization, ROS behave ambivalently in cancer progression. ROS facilitate carcinogenesis and cancer progression under mild-to-moderate elevated levels, whereas excessive ROS damages cancer cells dramatically, causing cell death ([@bib62], [@bib51]). Furthermore, as signaling messengers in the immune system, ROS are associated with tumor-induced immunosuppression in the tumor microenvironment by extensively participating in T cell activation, apoptosis, and hyporesponsiveness. Owing to this, we consider that ROS evoked from the mitoribosomal defects may play a crucial function in the suppressive immunity of the cancer microenvironment via TBRS. Meanwhile, TGF-β, which can promote ROS generation in the mitochondria of damaged hepatocytes, has been reported by directly downregulating antioxidative systems ([@bib1]). In this way, both TGF-β and ROS are building a strong interaction that provides an advantage to cancer cells to increment their malignancy. The mutual collaboration of TGF-β and ROS in mitoribosomal defect may be difficult to probe, due to their inherently complex and contradictory role in cancer progression ([@bib31]).

Although it is not clear how mitoribosome defects in HCC foster a cancer-favorable microenvironment and suppress anti-tumor immunity, we found that *SPP1*, *CSF1,* as well as *TGFB1* was highly enriched in the mitoribosome-defective tumor. Furthermore, activation of the S*PP1*/*CSF1*/*CSF1R* axis has been reported to provide the immunosuppressive nature of the HCC microenvironment and to be correlated with the increased expression of programmed cell death protein 1 (PD-1) ([@bib63]). Furthermore, the expression level of PD-1 is correlated with cellular ROS production and oxidative metabolism ([@bib53]). PD-1 is considered an immune checkpoint that controls T cell function, and the high expression of PD-1 is currently under investigation as a potential predictor of responses to anti-PD1 therapy ([@bib24], [@bib20], [@bib54]). As PD-1 maintains immune homeostasis by negatively regulating T cell function and survival, PD-1 blockade has been recently approved to treat patients with advanced-stage cancers by enhancing antitumor T cell immunity ([@bib52]). Furthermore, TGF-β inhibitors showed promise in several preclinical *in vitro* and *in vivo* studies ([@bib19]). Therefore, it would be interesting to stratify patients with HCC based on the magnitude of mitoribosomal defects and to explore the potential of combining ROS scavengers or TGF-β inhibitors with PD-1 signaling blockade for rapid clinical translation. Collectively, our findings demonstrate that mitoribosomal defect assessment may facilitate a survey of liver tumor immunity and stratification of patients for immune-based therapy.

Limitations of the Study {#sec3.1}
------------------------

In this study, we could not present the precise underlying mechanism of how mitoribosome defects in HCC upregulate the expression of *TGFB1* and activate TBRS. Also, we could not clarify how activated TBRS fosters a cancer-favorable microenvironment and suppresses anti-tumor immunity.
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### Material Availability {#sec3.2.2}
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All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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